1. Roscovitine: A Highly Selective CDK Inhibitor With Promising Oncology

    (R)-Roscovitine is often referred to as a “selective inhibitor of cyclin-dependent kinases.” Besides its use as a biological tool in cell cycle, neuronal functions, and apoptosis studies, it is currently evaluated as a potential drug to treat cancers, neurodegenerative diseases, viral infections, and glomerulonephritis.
  2. PI3K/Akt/mTOR Pathway: The Main Cancer Breakthrough

    The PI3K/AKT/mTOR pathway is central to cell growth and survival, cell cycle regulation, and programmed cell death.Aberrant activation of this signaling cascade is linked to several disease states, and thus many components of the pathway are attractive targets for therapeutic intervention.

2 Item(s)

To Top